{rfName}
Pr

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Garcia-Corbacho, JAuthor

Share

July 25, 2024
Publications
>
Article

Praluzatamab Ravtansine, a CD166-Targeting Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Publicated to: Clinical Cancer Research. 28 (10): 2020-2029 - 2022-05-15 28(10), DOI: 10.1158/1078-0432.ccr-21-3656

Authors:

Boni, V; Fidler, MJ; Arkenau, HT; Spira, A; Meric-Bernstam, F; Uboha, N; Sanborn, RE; Sweis, RF; LoRusso, P; Nagasaka, M; Garcia-Corbacho, J; Jalal, S; Harding, JJ; Kim, SK; Miedema, IHC; Vugts, DJ; Huisman, MC; Zwezerijnen, GJC; van Dongen, GAMS; van Oordt, CWMV; Wang, S; Dang, T; Zein, IA; Vasiljeva, O; Lyman, SK; Paton, V; Hannah, A; Liu, JF
[+]

Affiliations

Barbara Ann Karmanos Canc Inst - Author
CytomX Therapeut Inc - Author
Dana Farber Canc Inst - Author
HM Hosp, START Madrid HM CIOCC Ctr Integral Oncol Clara Ca, Hosp Univ HM Sanchinarro - Author
Hosp Clin Barcelona, Barcelona IDIBAPs - Author
Indiana Univ, Melvin & Bren Simon Canc Ctr - Author
Providence Canc Inst, Earle A Chiles Res Inst - Author
Robert Cizik Eye Clin - Author
Rush Univ, Med Ctr - Author
Sarah Cannon Res Inst UK Ltd - Author
Univ Chicago Med - Author
Univ Texas MD Anderson Canc Ctr - Author
Univ Wisconsin, Carbone Canc Ctr - Author
Virginia Canc Specialists - Author
Vrije Univ, Amsterdam UMC, Canc Ctr Amsterdam, Dept Radiol & Nucl Med - Author
Vrije Univ, Dept Med Oncol, Canc Ctr Amsterdam, Amsterdam UMC - Author
Weill Cornell Med Coll - Author
Yale Univ, Sch Med - Author
See more

Abstract

Purpose: Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. The tumor microenvironment is enriched for proteases capable of cleaving the linker, thereby releasing the mask, allowing for localized binding of CX-2009 to CD166. CX-2009 was evaluated in a phase I/II clinical trial for patients with advanced solid tumors. Patients and Methods: Eligible patients had metastatic cancer receiving >_2 prior treatments. CX-2009 was administered at escalating doses every 3 weeks (0.25???10 mg/kg) or every 2 weeks (4??? 6 mg/kg). Primary objective was to determine the safety profile and Results: Of 99 patients enrolled, the most prevalent subtype was breast cancer (n = 45). Median number of prior therapies
[+]

Keywords

Activated leukocyte cell adhesion moleculeAdhesion molecule alcam/cd166AdultAdvanced cancerAdverse eventAlpha1 glycoproteinAnemiaAntibody conjugateAntibody drug conjugateAntibody therapyAntigen bindingAntineoplastic agentAntineoplastic agentsAntitumorigenic activityArticleBackacheBreast cancerBreast neoplasmsBreast tumorCancer mortalityCancer patientCancer therapyCancer tissueClinical trialCohort analysisComputer assisted tomographyControlled studyDemographicsDesignDrug activityDrug dose escalationDrug receptor bindingDrug safetyDrug targetingDrug tolerabilityDrug withdrawalDyspneaEpidermal growth factor receptor 2Eye diseaseFemaleGlycoprotein synthesisHormone receptorHumanHuman cellHuman tissueHumansImmunoconjugatesKeratitisMajor clinical studyMaytansineMetastasisNauseaNeoplasmNeoplasmsPathologyPeripheral neuropathyPhase 1 clinical trialPhase 2 clinical trialPositron emission tomographyPraluzatamab ravtansineProtein expressionSepsisSolid malignant neoplasmTreatment outcomeTreatment responseTumor biopsyTumor microenvironmentTumor regressionUrticariaZirconium

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal CLINICAL CANCER RESEARCH due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 22/241, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 4.11. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 3.76 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-03, the following number of citations:

  • WoS: 43
  • Scopus: 47
  • Europe PMC: 9
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-03:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 66.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 66 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 70.
  • The number of mentions on the social network X (formerly Twitter): 12 (Altmetric).
  • The number of mentions in news outlets: 9 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Netherlands; United Kingdom; United States of America.

[+]